4.6 Post-Treatment Surveillance for Cancer Recurrence
Key Takeaways
- Surveillance is justified only when earlier detection changes outcome, which is why intensive imaging is standard after colorectal resection but not after curative breast surgery in an asymptomatic patient.
- ASCO and NCCN recommend against routine surveillance imaging and tumor markers in asymptomatic breast cancer survivors; history, physical examination, and annual mammography are the standard.
- Carcinoembryonic antigen every 3 to 6 months plus CT of the chest, abdomen, and pelvis is standard surveillance after curative-intent resection of stage II or III colorectal cancer, because resectable oligometastatic recurrence is curable.
- A rising tumor marker requires confirmation on a repeat draw and correlative imaging before any treatment decision, since benign conditions raise CEA, CA 19-9, and CA-125.
- Most solid tumor recurrences occur within the first 2 to 3 years, which is why surveillance is front-loaded, but late recurrence in hormone-receptor-positive breast cancer requires surveillance well beyond 5 years.
4.6 Post-Treatment Surveillance for Cancer Recurrence
Blueprint focus: ONCC Domain I.C.4 — Surveillance for primary cancer recurrence. Distinguish this from Domain I.A.3 (screening survivors for new primaries) and from survivorship care planning. Surveillance asks one question: has the original cancer come back?
The Governing Principle
Surveillance testing is worthwhile only when detecting recurrence earlier than symptoms would produce a better outcome. That test fails more often than clinicians expect.
- After curative-intent colorectal resection, it succeeds: isolated liver or lung metastases found early can be resected with curative intent, so intensive imaging and CEA surveillance are standard.
- After curative-intent breast surgery, it fails for distant disease: finding asymptomatic metastases earlier has repeatedly failed to improve survival in randomized trials, while generating false positives, radiation exposure, cost, and anxiety. Locoregional recurrence is potentially curable, however, which is why annual mammography and clinical examination remain standard.
This asymmetry explains nearly every disease-specific surveillance recommendation and is the most commonly tested concept in this blueprint item.
Timing: Front-Load the Schedule
Most solid tumor recurrences appear within the first 2 to 3 years, so visits and imaging are concentrated early and then spaced out. The important exception is hormone-receptor-positive breast cancer, where the risk of distant recurrence continues at a low steady rate for 20 years or more — which is why extended endocrine therapy and long-term follow-up are considered.
Disease-Specific Surveillance
| Cancer | Standard surveillance | Explicitly not recommended |
|---|---|---|
| Breast (post-curative treatment) | History and physical every 3 to 6 months for years 1 to 3, then every 6 to 12 months for years 4 to 5, then annually; annual mammography of remaining breast tissue; annual gynecologic assessment if on tamoxifen; bone density on aromatase inhibitors | Routine CT, PET, bone scan, or tumor markers (CA 15-3, CA 27.29, CEA) in asymptomatic patients |
| Colorectal (stage II to III after resection) | History and physical plus CEA every 3 to 6 months for 2 years then every 6 months to 5 years; CT chest/abdomen/pelvis annually (or more often in high-risk disease) for up to 5 years; colonoscopy at 1 year, then at 3 years, then every 5 years | PET as a routine surveillance modality |
| Non-small cell lung (after curative therapy) | CT chest every 6 months for 2 to 3 years, then annually; annual low-dose CT thereafter for new primaries | Routine brain MRI or PET in asymptomatic patients |
| Prostate (after prostatectomy or radiation) | PSA every 6 to 12 months for 5 years then annually; digital rectal examination annually | Routine imaging in the absence of PSA rise or symptoms |
| Melanoma | History and skin/nodal examination at intervals set by stage; imaging for stage IIB and above; lifelong full skin examination | Routine imaging for stage IA disease |
| Lymphoma | History, physical, and laboratory studies every 3 to 6 months for 2 years then less often; imaging as clinically indicated | Routine surveillance CT or PET in asymptomatic patients in remission, which produces frequent false positives |
| Head and neck | Examination every 1 to 3 months in year 1, tapering thereafter; baseline post-treatment imaging at about 3 months; TSH every 6 to 12 months after neck radiation | Indefinite frequent PET |
| Testicular germ cell | Stage- and histology-specific schedules of markers (AFP, beta-hCG, LDH) plus imaging | — |
Tumor Markers: Which Ones Actually Work
| Marker | Validated surveillance use | Caution |
|---|---|---|
| CEA | Colorectal cancer after curative resection | Elevated in smoking, hepatic disease, inflammatory bowel disease; not a screening test |
| PSA | Prostate cancer after definitive therapy | 5-alpha-reductase inhibitors roughly halve values; benign hyperplasia and prostatitis raise them |
| AFP, beta-hCG, LDH | Germ cell tumors | AFP rises in hepatic disease; beta-hCG rises in pregnancy and with marijuana use in some assays |
| CA-125 | Ovarian cancer follow-up (with the caveat that acting on marker rise alone before symptoms has not improved survival) | Rises with endometriosis, fibroids, pregnancy, peritoneal irritation |
| CA 19-9 | Pancreatic and biliary cancer trend | Not produced in Lewis-antigen-negative individuals (roughly 5% to 10% of people), and rises with biliary obstruction |
| Thyroglobulin | Differentiated thyroid cancer after total thyroidectomy | Requires simultaneous anti-thyroglobulin antibody measurement |
| CA 15-3 / CA 27.29 | Not recommended for routine breast cancer surveillance | Insufficient specificity to guide asymptomatic management |
Interpretation rule: a single elevated value is not a recurrence. Confirm on a repeat specimen from the same laboratory, look at the trend, and correlate with imaging and symptoms before changing treatment.
What Patients Should Be Taught to Report
Symptom-triggered evaluation detects more recurrences than any imaging schedule. Teach patients the specific red flags for their disease and tell them not to wait for the next scheduled visit:
- New or progressive pain, especially bone pain that is worse at night or at rest
- Unintentional weight loss, drenching night sweats, persistent fever
- A new lump, nodule, or change in a surgical scar or nodal basin
- Persistent cough, hemoptysis, or new dyspnea
- Change in bowel or bladder habit, rectal bleeding, hematuria
- New neurologic symptoms — headache, seizure, focal weakness, or back pain with weakness or bladder change, which is a spinal cord compression emergency
Working Up a Suspected Recurrence
- Take a focused history and examination targeted at the symptom.
- Obtain disease-appropriate imaging rather than reflexively ordering PET.
- Confirm histologically when the result would change management. Biology can change: a hormone-receptor-positive breast cancer can recur as receptor-negative disease, and a new lesion may be a second primary or a benign process.
- Re-biopsy for biomarkers at recurrence when resistance mechanisms are actionable — for example EGFR T790M or ESR1 mutations.
- Restage completely before treatment; a solitary resectable metastasis is a completely different clinical problem from widespread disease.
- Re-establish intent and goals explicitly, since recurrence usually shifts intent from curative to disease control and warrants palliative care integration.
The APRN's Role in Making Surveillance Actually Happen
Surveillance fails through attrition, not through ignorance. Document the schedule in the survivorship care plan, name which clinician orders each test, use recall systems rather than relying on patient memory, address transportation and cost barriers before they cause a missed scan, and manage the fear of recurrence that makes some survivors avoid appointments entirely and others seek unnecessary tests. Explaining why a test is not recommended is as much a part of surveillance as ordering the tests that are.
A 54-year-old woman is 18 months past lumpectomy, radiation, and adjuvant chemotherapy for stage II breast cancer. She is asymptomatic and her examination is normal. She asks for a PET scan and tumor markers 'just to be sure.' What is the most appropriate response?
A 61-year-old man had a curative resection of stage III colon cancer 14 months ago. His CEA has risen from 2.1 to 4.8 to 9.4 ng/mL over three consecutive draws, and he is asymptomatic. What is the most appropriate next step?
A patient with a history of hormone-receptor-positive, HER2-negative breast cancer develops a solitary liver lesion 6 years after completing adjuvant therapy. Imaging is consistent with metastasis. Beyond restaging, which additional step is most important before selecting systemic therapy?